Premium
Cost of screening for cancerous and precancerous lesions of the cervix
Author(s) -
Méréa Estelle,
Le Galès Catherine,
CochandPriollet Beatrix,
Cartier Isabelle,
de Crémoux Patricia,
VacherLavenu Marie Cécile,
Vielh Philippe,
Coste Joël
Publication year - 2002
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/dc.10177
Subject(s) - medicine , cervix , cytology , human papillomavirus , cervical cancer , gynecology , test (biology) , population , thin layer , medical physics , cancer , pathology , layer (electronics) , environmental health , paleontology , chemistry , organic chemistry , biology
This paper is part of the cost‐effectiveness study of cervical cancer screening conducted by the French Society of Clinical Cytology (SFCC). It describes the evaluation of costs of conventional smear tests, thin‐layer smear tests (ThinPrep 2000 system), and viral typing by the HCS® test. For 100,000 examinations per year, the average cost of a conventional smear test is $11.53 in a private anatomo‐pathology clinic. The cost of the thin‐layer test for the same number of examinations and in the same type of clinic is $13.93. For 20,000 annual tests, the average cost of human papillomavirus (HPV) is $23.43 in the public sector and $23.48 in the private one. The higher price of the thin‐layer method is only justifiable if this screening technique outperforms the conventional method. Furthermore, the high cost of the HPV test means that its integration into a population‐based screening program must be carefully defined. Diagn. Cytopathol. 2002;27:251–257. © 2002 Wiley‐Liss, Inc.